(Q28253140)

English

Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety

scientific article

In more languages

Statements

scholarly article

0 references

Treatment of Crohn's disease with leflunomide as second-line immunosuppression : a phase 1 open-label trial on efficacy, tolerability and safety (English)

0 references

phase I clinical trial

0 references

Crohn's disease

0 references

immunosuppression

1 reference

based on heuristic

inferred from title

5

object named as

Markus F Neurath

0 references

author name string

Martin H Holtmann

1

0 references

Anna-Lena Gerts

2

0 references

Arndt Weinman

3

0 references

Peter R Galle

4

0 references

language of work or name

0 references

publication date

April 2008

0 references

Digestive Diseases and Sciences

0 references

53

0 references

4

0 references

1025-32

0 references

The role of Th1/Th2 polarization in mucosal immunity

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is the recommended dose of leflunomide the best regimen to treat rheumatoid arthritis patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Methotrexate for induction of remission in refractory Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Advances in the treatment of Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action for leflunomide in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17934840

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-007-9953-7

0 references

Dimensions Publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28253140&oldid=2177545793"